经导管主动脉瓣植入术的人造瓣膜研究进展  

Research Advances in Artificial Valves in the Procedure of Transcatheter Aortic Valve Replacement

作　　者：贾圣琪 裴汉军[2] JIA Shengqi;PEI Hanjun(Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014040,China;Department of Cardiology,the First Affiliated Hospital of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014010,China)

机构地区：[1]内蒙古科技大学包头医学院,内蒙古包头014040 [2]内蒙古科技大学包头医学院第一附属医院心内科,内蒙古包头014010

出　　处：《医学综述》2018年第6期1144-1148,共5页Medical Recapitulate

摘　　要：目前,主动脉瓣狭窄(AS)相对有效的治疗措施有两种,即外科手术治疗和介入治疗。虽然外科手术仍是AS的标准治疗手段,但近年来经导管主动脉瓣植入术(TAVR)日臻成熟,适应证由原来的外科手术高危组、极高危组患者向中危组甚至低危组患者群体拓展。随着TAVR技术的兴起,人工瓣膜存在的问题也逐渐显现。其中,术后血管并发症、卒中、瓣周漏、心脏传导异常的发生,以及术后耐久性都是目前临床上较为重视的问题。如何改进人工瓣膜的性能,减少并发症的发生,人工生物瓣膜的研发正在进行。At present,there are two relatively effective treatments for aortic stenosis(AS):surgical treatment and interventional therapy.Although surgery remains the standard treatment of AS,with the development of transcatheter aortic valve replacement(TAVR)in recent years,the indications extended from the high-risk and the extremely high-risk patients to the moderate risk,even low-risk patients.With the rise of TAVR,the problems of artificial valves are gradually emerging.Among all of the problems,the incidence of postoperative vascular complications,stroke,paravalvular leak,conduction abnormalities and the valve durability of postoperation are the most important issues in clinical practice.How to improve the efficacy and reduce the complication are the focuses of recent studies.

关 键 词：主动脉瓣狭窄 经导管主动脉瓣植入术 人工生物瓣膜 

分 类 号：R542.52[医药卫生—心血管疾病]